Avita Medical (NASDAQ:RCEL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Avita Medical (NASDAQ:RCEL – Free Report) from a hold rating to a buy rating in a report published on Saturday,Wall Street Zen reports.

RCEL has been the topic of a number of other research reports. Lake Street Capital raised their price target on Avita Medical from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. BTIG Research lifted their price target on Avita Medical from $15.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. TD Cowen boosted their price objective on Avita Medical from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, November 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Get Our Latest Research Report on Avita Medical

Avita Medical Price Performance

NASDAQ RCEL opened at $15.22 on Friday. Avita Medical has a 1 year low of $3.22 and a 1 year high of $18.43. The company has a market capitalization of $478.21 million, a PE ratio of -12.90 and a beta of 2.03. The company has a fifty day moving average of $13.48 and a two-hundred day moving average of $7.22.

Avita Medical (NASDAQ:RCEL – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. The firm had revenue of $26.11 million for the quarter, compared to analysts’ expectations of $22.35 million. On average, research analysts expect that Avita Medical will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Avita Medical

A number of institutional investors and hedge funds have recently made changes to their positions in RCEL. BlackRock Inc. purchased a new stake in shares of Avita Medical during the second quarter worth approximately $2,333,000. Marshall Wace LLP lifted its holdings in shares of Avita Medical by 107.1% during the third quarter. Marshall Wace LLP now owns 700,745 shares of the company’s stock worth $8,220,000 after purchasing an additional 362,358 shares during the period. Goldman Sachs Group Inc. grew its position in Avita Medical by 247.4% in the 3rd quarter. Goldman Sachs Group Inc. now owns 266,595 shares of the company’s stock valued at $3,127,000 after buying an additional 189,858 shares during the last quarter. NewEdge Advisors LLC grew its position in Avita Medical by 8,588.5% in the 1st quarter. NewEdge Advisors LLC now owns 86,885 shares of the company’s stock valued at $321,000 after buying an additional 85,885 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in Avita Medical in the 2nd quarter valued at $213,000. 27.66% of the stock is owned by hedge funds and other institutional investors.

About Avita Medical

(Get Free Report)

AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.

Recommended Stories

Analyst Recommendations for Avita Medical (NASDAQ:RCEL)

Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.